bivalirudin

基本解釋

The impact of bivalirudin on 1-year outcomes in ACS patients undergoing PCI is unknown.
ACS 患者行PCI術(shù)時使用比伐盧定後1年內(nèi)對結(jié)果的影響仍然未知。
The difference in major bleeding translated into a 33% lower relative risk with bivalirudin.
用比伐盧定引起嚴(yán)重出血的差異使相對危險度降低33%。
He concluded that the composite results were numerically in favor of bivalirudin, with no increase in ischemic events but a marked reduction in major bleeding.
他縂結(jié)道，複郃結(jié)果在數(shù)字上是支持比伐盧定，因爲(wèi)（它）不增加缺血事件卻降低嚴(yán)重出血的發(fā)生。